Visceral adipose tissue and liver fat on 17-beta estradiol-dominant gender-affirming hormone therapy: A US-based cohort - Takeaways - MDSpire

Visceral adipose tissue and liver fat on 17-beta estradiol-dominant gender-affirming hormone therapy: A US-based cohort

  • By

  • Ria Talathi

  • Vencel Juhasz

  • Matilda Delgado

  • Thiago Quinaglia

  • Azin Ghamari

  • Melissa Wang

  • Iad Alhallak

  • Sarah Stinebaugh

  • Sophia Campbell

  • Sara L Stockman

  • Mustafa A Ozturk

  • Sadia M Ahmadi

  • Sara E Looby

  • Hang Lee

  • Tonia C Poteat

  • Lidia S Szczepaniak

  • Markella V Zanni

  • Tomas G Neilan

  • Mabel Toribio

  • December 12, 2025

  • 0 min

Share

  • 1

    The study assessed the metabolic effects of gender-affirming hormone therapy (GAHT) in transgender women and nonbinary individuals over 12 months.

  • 2

    Visceral adipose tissue mass and volume remained unchanged after 12 months of GAHT, indicating no adverse effects on this key metabolic parameter.

  • 3

    Bone density increased at lumbar, total hip, and femoral sites, while insulin sensitivity did not show significant changes during the study.

  • 4

    Intrahepatic triglyceride content decreased significantly, suggesting a favorable metabolic effect of GAHT on hepatic fat.

  • 5

    Total lean body mass decreased, highlighting potential risks of sarcopenia associated with GAHT despite improvements in hepatic lipid profiles.

Original Source(s)

Related Content